NASDAQ:PRTA Prothena Q2 2023 Earnings Report $6.22 -0.21 (-3.27%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$6.25 +0.03 (+0.47%) As of 08:32 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Prothena EPS ResultsActual EPS-$1.03Consensus EPS -$0.92Beat/MissMissed by -$0.11One Year Ago EPS-$0.88Prothena Revenue ResultsActual Revenue$4.02 millionExpected Revenue$5.09 millionBeat/MissMissed by -$1.07 millionYoY Revenue Growth+206.30%Prothena Announcement DetailsQuarterQ2 2023Date8/3/2023TimeAfter Market ClosesConference Call DateThursday, August 3, 2023Conference Call Time4:00PM ETUpcoming EarningsProthena's Q2 2025 earnings is scheduled for Wednesday, August 6, 2025, with a conference call scheduled on Thursday, August 7, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Prothena Earnings HeadlinesProthena Corp (PRTA) Receives Reiterated Neutral Rating from Cantor Fitzgerald | PRTA Stock NewsJune 20, 2025 | gurufocus.comRoche’s Phase 3 Move Boosts Outlook for Prothena Corporation plc (PRTA)June 19, 2025 | finance.yahoo.comThis Cold War “Accident” Could Unleash New $100 Trillion AI BoomObscure Metal More Valuable than Gold and Bitcoin… COMBINED? This strange "AI Metal" holds the key to the $100 trillion AI boom. Which is why Jeff Brown recently traveled to a location that has one of the highest concentrations of this metal in the world. And you won't believe what he uncovered.July 16 at 2:00 AM | Brownstone Research (Ad)Prothena Announces Corporate RestructuringJune 18, 2025 | finance.yahoo.comRoche’s Phase 3 Move Boosts Outlook for Prothena Corporation plc (PRTA)June 17, 2025 | msn.comProthena’s Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's DiseaseJune 16, 2025 | uk.finance.yahoo.comSee More Prothena Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Prothena? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Prothena and other key companies, straight to your email. Email Address About ProthenaProthena (NASDAQ:PRTA) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for neurodegenerative and rare peripheral diseases. The company leverages its proprietary platform technologies to design and engineer monoclonal antibodies and small molecules that target disease-causing proteins. Core research activities center on immunotherapy approaches aimed at clearing or neutralizing pathological protein aggregates. Prothena’s pipeline includes several lead assets in clinical development. PRX002/RG7935 is an anti–alpha-synuclein antibody being investigated for Parkinson’s disease, in collaboration with Roche. PRX004 is directed at serum amyloid A in patients with AA amyloidosis, while PRX012 targets interleukin-13 for the treatment of moderate-to-severe atopic dermatitis. The company also maintains a robust preclinical portfolio addressing other protein misfolding disorders and has partnered with industry leaders to advance select candidates into human trials. Founded in 2012 as a spin-out from Elan Corporation, Prothena is headquartered in Dublin, Ireland, with research and development operations in South San Francisco. The company’s global footprint spans North America and Europe, enabling access to diverse patient populations and facilitating multinational clinical studies. Prothena’s integrated development infrastructure supports seamless progression from discovery through late-stage development. Under the leadership of Chief Executive Officer Gene Kinney, Prothena is guided by a management team with extensive experience in biopharmaceutical development, regulatory strategy and commercial planning. With a focus on addressing high-unmet medical needs, the company aims to translate its scientific insights into first-in-class and best-in-class therapies for patients worldwide.Written by Jeffrey Neal JohnsonView Prothena ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles 3 Analysts Set $600 Target Ahead of Microsoft EarningsTesla: 2 Plays Ahead of Next Week's Earnings ReportFastenal Surges After Earnings Beat, Tariff Risks Loom3 Catalysts Converge on Intel Ahead of a Critical Earnings ReportSmith & Wesson Stock Falls on Earnings Miss, Tariff WoesWhat to Expect From the Q2 Earnings Reporting CycleBroadcom Slides on Solid Earnings, AI Outlook Still Strong Upcoming Earnings Interactive Brokers Group (7/17/2025)PepsiCo (7/17/2025)Cintas (7/17/2025)Netflix (7/17/2025)American Noble Gas (7/17/2025)U.S. Bancorp (7/17/2025)Novartis (7/17/2025)Abbott Laboratories (7/17/2025)Marsh & McLennan Companies (7/17/2025)Taiwan Semiconductor Manufacturing (7/17/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
